Economics of treatment with GnRH agonist 7–14days after artificial insemination in repeat breeder lactating dairy cows

• Published in: Reproduction in domestic animals 2023-07, Vol.58 (7), p.929-934
• Main Authors: Silviu‐Ionuț Borş, Borş, Alina, Ahmed Sabry S Abdoon
• Format: Article
• Language: English
• Subjects: Agonists; Artificial insemination; Cattle; Corpus luteum; Dairy cattle; Decision support systems; Embryos; Gonadotropin-releasing hormone; Milk; Pregnancy; Survival
• ISSN: 0936-6768; 1439-0531
• DOI: 10.1111/rda.14368

This study looked at the effectiveness and financial benefits of treating repeat breeder (RB) dairy cows with the GnRH agonist gonadorelin 7–14 days after artificial insemination (AI). A total of 188 healthy dairy cows (2.4 ± 1.3 lactations) with an average milk yield of 42.1 ± 6.8 kg milk/day, at 179 ± 38.4 days in milk with 3.8 ± 1 AIs were divided into two groups, experimental (E group, n = 98) and control (C group, n = 90). The GnRH agonist gonadorelin was given 7–14 days after AI to the E group to evaluate the embryo survival in RB cows. The control group did not receive any treatment. Recorded pregnancy rates and cumulative pregnancy rates were superior in the E group (49% and 64.3%) compared with the C group (37.8% and 55.5%). The interaction between therapy and RB had a significant impact on the pregnancy rate and accessory corpus luteum (CL), according to a binary logistic regression study. The UW‐DairyRepro$ decision support tool utilized in this experiment demonstrated that by implementing this approach, the net present value can be increased by US dollars (US$)30.2/RB cow/year. Thus, the single therapy with GnRH agonist gonadorelin between 7 and 14 days after AI enhanced the potential for a second CL in repeat‐breeder pregnant cows, presumably favouring embryo survival.